Sole Claudio V, Calvo Felipe A, Lizarraga Santiago, Gonzalez-Bayon Luis, Segundo Carmen Gonzalez San, Desco Manuel, García-Sabrido Jose L
Service of Radiation Oncology, Instituto de Radiomedicina, Santiago, Chile.
Health Research Institute, Hospital Gregorio Marañón, Madrid, Spain.
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1247-55. doi: 10.1245/s10434-015-4604-2. Epub 2015 May 13.
The aim of this study was to analyze long-term outcomes and prognostic factors associated with survival in patients with locoregional oligo-recurrent (LROR) pelvic malignancies treated in a multimodal protocol.
Patients with an histologic diagnosis of LROR pelvic cancer (rectal 50 %, gynecological 50 %) with absence of distant metastases, undergoing surgery with radical intent and intraoperative radiotherapy (median dose 12.5 Gy) were considered eligible for participation in this study. Additionally, 48 % received external beam radiotherapy (EBRT) (median dose 50 Gy).
From 1995 to 2012, a total of 143 patients from a single institution were analyzed. With a median follow-up time of 48 months (range 2-189), 5-year locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) were 53, 44, and 46 %, respectively. On multivariate analysis, no EBRT treatment to the locoregional (p ≤ 0.001), R1 margin status (p = 0.03), time interval from primary tumor diagnosis to LROR <24 months (p = 0.05), and fragmentation in the resected specimen (p = 0.004) retained significance in relation to LRC. On multivariate analysis we found that only R1 margin status (p = 0.003), primary tumor diagnosis to LROR <24 months (p = 0.02), and high histological grade (p = 0.02) were significantly associated with OS.
From this analysis emerges the fact that EBRT influences local control but, given the high risk of distant metastases, DFS remains modest. Margin status, tumor fragmentation, no EBRT to the LR, and time interval from primary tumor diagnosis to LROR are the dominant factors for subsequent locoregional recurrence (LRR). Accordingly, future prospective studies might be designed which adapt treatment according to the predicted risk of subsequent LRR.
本研究旨在分析采用多模式方案治疗的局部区域寡复发(LROR)盆腔恶性肿瘤患者的长期预后及与生存相关的预后因素。
组织学诊断为LROR盆腔癌(直肠癌占50%,妇科肿瘤占50%)且无远处转移、接受根治性手术及术中放疗(中位剂量12.5 Gy)的患者被认为符合参与本研究的条件。此外,48%的患者接受了外照射放疗(EBRT)(中位剂量50 Gy)。
1995年至2012年,对来自单一机构的143例患者进行了分析。中位随访时间为48个月(范围2 - 189个月),5年局部区域控制率(LRC)、无病生存率(DFS)和总生存率(OS)分别为53%、44%和46%。多因素分析显示,未对局部区域进行EBRT治疗(p≤0.001)、R1切缘状态(p = 0.03)、从原发性肿瘤诊断到LROR的时间间隔<24个月(p = 0.05)以及切除标本中的破碎情况(p = 0.004)与LRC仍具有显著相关性。多因素分析发现,只有R1切缘状态(p = 0.003)、从原发性肿瘤诊断到LROR<24个月(p = 0.02)以及高组织学分级(p = 0.02)与OS显著相关。
从该分析得出,EBRT影响局部控制,但鉴于远处转移风险高,DFS仍然不高。切缘状态、肿瘤破碎情况、未对LR进行EBRT治疗以及从原发性肿瘤诊断到LROR的时间间隔是后续局部区域复发(LRR)的主要因素。因此,未来可能设计前瞻性研究,根据预测的后续LRR风险调整治疗方案。